PRQR stock forecast, quote, news & analysis
ProQR Therapeutics NV is a biopharmaceutical company... Show more
Why ProQR Therapeutics (PRQR) Stock Is Down -14% in the Last 30 Days
Key Takeaways
- ProQR Therapeutics (PRQR) shares fell roughly 14% over the past 30 days, declining from $1.57 to $1.35 per share.
- The move extends a broader pullback from the stock's late-August peak near $2.43, reflecting a sustained multi-month downtrend.
- No single dramatic catalyst triggered the slide; the decline reflects a steady drift tied to post-rally consolidation and ongoing clinical-stage risk.
- The company continues to advance its Axiomer RNA-editing pipeline, dosing the first participant in its Phase 1 AX-0811 study in September 2026.
- Third-quarter 2026 results were scheduled for early November, keeping traders positioned cautiously ahead of the print.
- Analysts maintained Buy ratings with price targets well above the market price, including Cantor Fitzgerald at $8 and Oppenheimer at $9.
- For additional details on this ticker's valuation and outlook, explore the Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading strategies are positioning across the market.
ProQR Therapeutics (PRQR) Company Overview and Market Position
ProQR Therapeutics N.V. is a clinical-stage biotechnology company headquartered in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts. The company focuses on developing transformative RNA therapies built on its proprietary Axiomer platform, which uses the cell's own ADAR editing machinery to make precise single-nucleotide edits in RNA. This approach is designed to reverse disease-causing mutations or modulate protein expression, potentially yielding a new class of medicines for both rare and prevalent diseases.
ProQR's pipeline includes AX-0810 and AX-0811, both targeting cholestatic liver diseases, as well as development candidates AX-2402 for Rett syndrome and AX-2911 for MASH. The company has a strategic collaboration with Eli Lilly, which holds an ownership stake and provides milestone-based funding. Investors follow PRQR closely for clinical readouts that could validate the Axiomer platform across a broad set of therapeutic applications.
ProQR Therapeutics (PRQR) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PRQR shares declined approximately 14%, falling from $1.57 to $1.35. The move was not a single-day crash but rather a steady, stepwise slide punctuated by intermittent bounces. The stock traded near $1.63 in early October before breaking lower through the month and settling around the low-$1.30s by early November.
The quarterly picture is more pronounced. Measured from early August, when shares closed near $1.88, the stock is down roughly 28% through early November. Notably, the quarter included a sharp mid-August rally that pushed the stock to an intra-quarter peak near $2.43 before a sustained decline began. In short, the recent 30-day weakness is part of a larger, multi-month downtrend rather than an isolated event.
What Drove PRQR Stock Price in the Last 30 Days
The 30-day decline does not appear tied to a single, widely reported negative event. Instead, several factors likely contributed to sustained selling pressure. First, the stock had surged in mid-August following positive analyst coverage, creating a setup vulnerable to profit-taking as momentum faded. Second, as a clinical-stage biotech, PRQR remains sensitive to broader risk appetite, and small-cap healthcare names faced uneven sentiment during the period.
On the operational front, the company continued to make pipeline progress rather than deliver negative news. In September, ProQR announced the first participant dosed in the Phase 1 study of AX-0811, and it appointed new AI-focused leadership. In late October, it disclosed plans to present AX-0810 and AX-0811 data at major conferences. However, the upcoming third-quarter earnings report scheduled for early November kept traders cautious, and investors remained mindful of the company's financing history, including a June 2026 share offering priced at $1.81 per share. The combination of post-rally consolidation, pre-earnings caution, and lingering dilution considerations best explains the gradual retreat.
What Drove PRQR Stock Performance Over the Last Quarter
The broader quarterly trend has been defined by a sharp rally followed by an extended unwind. In August, PRQR received fresh Buy initiations and reiterations from several firms, with price targets as high as $8 to $9, which helped drive the stock from the low-$1.80s toward $2.43. That enthusiasm was not sustained.
As the quarter progressed, the absence of near-term clinical catalysts and the inherently speculative nature of an early-stage RNA-editing platform weighed on sentiment. The company's cash runway into mid-2027 provides operating flexibility, but investors have also weighed the dilutive effects of prior financings. Over the quarter, the stock gave back its August gains and then some, underscoring how quickly biotech sentiment can shift without a confirming data catalyst.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. While Tickeron offers hundreds of bots trading thousands of tickers, only the top-performing and most relevant strategies appear in this section. The bots vary in strategy, timeframe, and performance metrics, allowing users to review different approaches rather than a single one-size-fits-all system. The page is designed to help traders and investors identify automated strategies that are currently generating attention, and it can serve as a useful reference for those exploring algorithmic approaches to the market.
PRQR Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will likely focus on several key factors. Quarterly earnings and updated guidance remain central, alongside any commentary on cash runway and future financing plans. Clinical progress is equally important, particularly target engagement and safety data from the AX-0810 Phase 1 program, which management has indicated is expected in the first half of 2026, as well as continued enrollment in the AX-0811 study.
Broader considerations include the pace of the company's AI-enabled drug discovery efforts, competitive developments in the RNA-editing space, and general risk appetite for small-cap biotech names. Conference presentations, such as those at AASLD and TIDES Europe, may also shape sentiment. As always, clinical-stage companies carry substantial execution risk, and investors should weigh these catalysts against the inherent uncertainty of early development.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PRQR in upward trend: price may jump up because it broke its lower Bollinger Band on October 13, 2026
PRQR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 38 cases where PRQR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PRQR's RSI Oscillator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for PRQR just turned positive on October 28, 2026. Looking at past instances where PRQR's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.
Following a +3.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRQR advanced for three days, in 173 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 59 cases where PRQR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRQR as a result. In 82 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The 50-day moving average for PRQR moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRQR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for PRQR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.397) is normal, around the industry mean (3.498). P/E Ratio (-3.375) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.294) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. PRQR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRQR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company with interest in the discovery and development of therapeutics for the treatment of genetic disorders
Industry Biotechnology